2,4-Dinitrophenol as an Uncoupler Augments the Anthracyclines Toxicity against Prostate Cancer Cells

Grzegorz Adamczuk1, Ewelina Humeniuk1, Kamila Adamczuk2

  • 1Independent Medical Biology Unit, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.

Insights

The compound 2,4-dinitrophenol (2,4-DNP) enhances prostate cancer cell sensitivity to chemotherapy by disrupting energy metabolism. This combination increases oxidative stress, leading to cancer cell death.

Area of Science:

  • Biochemistry
  • Oncology
  • Cell Biology

Background:

  • Targeting cancer cell energy metabolism is a key treatment strategy.
  • 2,4-dinitrophenol (2,4-DNP) disrupts cellular energy production by uncoupling oxidative phosphorylation.

Purpose of the Study:

  • To investigate if 2,4-DNP can sensitize prostate cancer cells to anthracyclines (doxorubicin, epirubicin).
  • To evaluate the synergistic effects and underlying mechanisms of 2,4-DNP combined with anthracyclines.

Main Methods:

  • MTT assay for cell viability.
  • Apoptosis detection and cell cycle analysis.
  • Assessment of oxidative stress using CellROX, cellular thiols, and DNA damage markers.

Main Results:

  • 2,4-DNP demonstrated a synergistic effect with doxorubicin and epirubicin in LNCaP prostate cancer cells.
  • The combination therapy significantly increased oxidative stress, reduced cellular thiols, and elevated DNA oxidative damage (AP sites).
  • LNCaP cells showed higher sensitivity to anthracyclines compared to PC-3 and DU-145 cell lines.

Conclusions:

  • 2,4-DNP enhances anthracycline efficacy in prostate cancer by inhibiting ATP synthesis and inducing ROS production, leading to mitochondrial damage.
  • This combination therapy offers a potential strategy for treating advanced prostate cancer, particularly in cell lines with an oxidative phenotype.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...